World Antimicrobial Resistance (AMR) Awareness Week 2026: Broad coalition calls for policy decisions to support new antibiotics in Germany
Open letter to the German federal government: Create new incentives, provide targeted support for reserve antibiotics, and ensure the long-term sustainability of research infrastructure
On the occasion of the Global Action Week Against Antimicrobial Resistance (WAAW), taking place November 18–24, the German Network Against Antimicrobial Resistance (DNAMR) and its supporters in medicine, research, and the healthcare industry, including the German Center for Infection Research (DZIF), has addressed an open letter to the federal government.
Under the title "New Antibiotics. New Reserve Antibiotics. Support Them Now", the alliance is calling for decisive political action to advance the development of new antibiotics, ensure their long-term availability, and strengthen the research infrastructure for combating antimicrobial resistance. The coalition has formulated four key demands:
- Recognize the societal value of new antibiotics
- Reward availability rather than consumption, for example, by participating in the implementation of the Transferable Exclusivity Voucher (TEV) and the Voluntary Subscription Model (VSM).
- Provide targeted support for reserve antibiotics
- Ensure the long-term sustainability of research and surveillance. This can be achieved by investing in translational research and organizations such as DZIF, INCATE and CARB-X, that advance the development of new antimicrobial agents.
The open letter is supported by stakeholders from various sectors of the healthcare system—including professional societies for infectious diseases, oncology, and pediatric infectious diseases; research institutions; antibiotic research organizations; representatives of the pharmaceutical industry; and other experts.
This broad support underscores that antimicrobial resistance is not a challenge faced solely by infectious disease medicine. It affects the entire modern healthcare system and requires collaborative solutions that transcend disciplinary and sectoral boundaries.
The joint appeal is as follows:
New antibiotics must be developed and made available before they become urgently needed. A reliable policy framework is needed now to make this happen.